Sonnet Biotherapeutics Holdings Inc (SONN)

$2.65 -0.16 (-5.69%)
Market Cap 8.90M
Revenue (ttm) 20,000.00
Net Income (ttm) -7.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -37,200.00%
Debt to Equity Ratio 0.00
Volume 522,897
Avg Vol 4,791,794
Day's Range N/A - N/A
Shares Out 3.17M
Stochastic %K 8%
Beta 1.03
Analysts Strong Sell
Price Target $20.00

Company Profile

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cance...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 375 2227
Address:
100 Overlook Center, Suite 102, Princeton, United States
CometaMan
CometaMan Aug. 5 at 3:32 PM
$SONN I bought some yesterday at $2.58 and sold $2.84. I’d like to do it again please.
0 · Reply
CometaMan
CometaMan Aug. 5 at 3:29 PM
$SONN i am getting me some when it drops to $2.58
0 · Reply
949Jaguar123
949Jaguar123 Aug. 4 at 5:29 PM
$SONN Give me the good and the bad I might buy a few here ? This is got to be a 10 d. stock ?
1 · Reply
949Jaguar123
949Jaguar123 Aug. 4 at 5:27 PM
$SONN What the heck is going on here, didn't they buy like a ton of HYPE coin and they only have a 5-6m. float ???
1 · Reply
Mg_1970
Mg_1970 Aug. 4 at 5:19 PM
$SONN Bear trap 😎👊
0 · Reply
Mg_1970
Mg_1970 Aug. 4 at 4:56 PM
$SMX Take an eye at $SONN if it breaks $3
0 · Reply
Mg_1970
Mg_1970 Aug. 4 at 4:53 PM
$SONN Excellent reaction 😎👍
0 · Reply
dogood
dogood Aug. 4 at 4:00 PM
$SONN firing to break $3 now
0 · Reply
dogood
dogood Aug. 4 at 3:50 PM
$SONN aren’t suppose to be green
0 · Reply
Bazzzigar
Bazzzigar Aug. 4 at 3:22 PM
$SONN JUNK
0 · Reply
Latest News on SONN
Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Aug 4, 2025, 8:40 AM EDT - 1 day ago

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?

Jul 14, 2025, 11:30 AM EDT - 22 days ago

Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

Jul 14, 2025, 6:00 AM EDT - 22 days ago

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

May 1, 2025, 9:00 AM EDT - 3 months ago

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

Sonnet Releases Virtual Investor "What This Means" Segment

Apr 16, 2025, 9:10 AM EDT - 3 months ago

Sonnet Releases Virtual Investor "What This Means" Segment

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Apr 4, 2025, 9:00 AM EDT - 4 months ago

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Sonnet Announces Release of Corporate Update Video

Apr 1, 2025, 4:15 PM EDT - 4 months ago

Sonnet Announces Release of Corporate Update Video

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Apr 1, 2025, 7:30 AM EDT - 4 months ago

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Mar 26, 2025, 9:05 AM EDT - 4 months ago

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Mar 19, 2025, 8:50 AM EDT - 4 months ago

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Mar 11, 2025, 8:45 AM EDT - 5 months ago

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Feb 26, 2025, 9:00 AM EST - 5 months ago

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Feb 19, 2025, 8:35 AM EST - 5 months ago

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Feb 18, 2025, 9:15 AM EST - 6 months ago

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Feb 13, 2025, 8:30 AM EST - 6 months ago

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Feb 13, 2025, 8:00 AM EST - 6 months ago

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Jan 28, 2025, 9:05 AM EST - 6 months ago

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 22, 2025, 8:35 AM EST - 6 months ago

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Jan 21, 2025, 9:05 AM EST - 7 months ago

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Dec 23, 2024, 9:20 AM EST - 8 months ago

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Dec 17, 2024, 8:50 AM EST - 8 months ago

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 9, 2024, 3:42 PM EST - 8 months ago

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

Dec 9, 2024, 8:45 AM EST - 8 months ago

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

Dec 4, 2024, 9:20 AM EST - 8 months ago

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Nov 12, 2024, 9:15 AM EST - 9 months ago

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

Nov 6, 2024, 1:20 PM EST - 9 months ago

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Nov 6, 2024, 8:30 AM EST - 9 months ago

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

Oct 17, 2024, 8:45 AM EDT - 10 months ago

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Oct 9, 2024, 8:45 AM EDT - 10 months ago

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

Oct 4, 2024, 8:30 AM EDT - 10 months ago

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

Sep 30, 2024, 9:00 AM EDT - 11 months ago

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

Sep 25, 2024, 8:30 AM EDT - 11 months ago

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

Sep 18, 2024, 8:30 AM EDT - 11 months ago

Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series

Sep 4, 2024, 9:15 AM EDT - 11 months ago

Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Aug 19, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer

Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 8:35 AM EDT - 1 year ago

Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

Jul 24, 2024, 3:00 PM EDT - 1 year ago

Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study

Jul 24, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study

Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting

May 28, 2024, 8:00 AM EDT - 1 year ago

Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

May 20, 2024, 9:15 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update

May 14, 2024, 4:15 PM EDT - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference

May 6, 2024, 7:00 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting

Mar 19, 2024, 7:30 AM EDT - 1 year ago

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting

Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective

Mar 11, 2024, 7:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers

Feb 29, 2024, 4:05 PM EST - 1 year ago

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update

Feb 14, 2024, 7:30 AM EST - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy

Dec 21, 2023, 8:00 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update

Dec 14, 2023, 4:15 PM EST - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview

Oct 31, 2023, 7:30 AM EDT - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview

CometaMan
CometaMan Aug. 5 at 3:32 PM
$SONN I bought some yesterday at $2.58 and sold $2.84. I’d like to do it again please.
0 · Reply
CometaMan
CometaMan Aug. 5 at 3:29 PM
$SONN i am getting me some when it drops to $2.58
0 · Reply
949Jaguar123
949Jaguar123 Aug. 4 at 5:29 PM
$SONN Give me the good and the bad I might buy a few here ? This is got to be a 10 d. stock ?
1 · Reply
949Jaguar123
949Jaguar123 Aug. 4 at 5:27 PM
$SONN What the heck is going on here, didn't they buy like a ton of HYPE coin and they only have a 5-6m. float ???
1 · Reply
Mg_1970
Mg_1970 Aug. 4 at 5:19 PM
$SONN Bear trap 😎👊
0 · Reply
Mg_1970
Mg_1970 Aug. 4 at 4:56 PM
$SMX Take an eye at $SONN if it breaks $3
0 · Reply
Mg_1970
Mg_1970 Aug. 4 at 4:53 PM
$SONN Excellent reaction 😎👍
0 · Reply
dogood
dogood Aug. 4 at 4:00 PM
$SONN firing to break $3 now
0 · Reply
dogood
dogood Aug. 4 at 3:50 PM
$SONN aren’t suppose to be green
0 · Reply
Bazzzigar
Bazzzigar Aug. 4 at 3:22 PM
$SONN JUNK
0 · Reply
dogood
dogood Aug. 4 at 3:05 PM
$SONN not sure what will trigger this to run above $3
0 · Reply
Mg_1970
Mg_1970 Aug. 4 at 1:57 PM
$SONN Bought 2000 at 2.695 avg 🤞🙄
0 · Reply
dogood
dogood Aug. 4 at 1:55 PM
$SONN should have been $5
0 · Reply
dogood
dogood Aug. 4 at 12:56 PM
$SONN $4?
1 · Reply
dbr_island
dbr_island Aug. 4 at 12:44 PM
$SONN there it goes VCIG is next Here’s why👇🚨🚨🚨
0 · Reply
Ilikethestock89
Ilikethestock89 Aug. 4 at 12:43 PM
$SONN so whats gonna be today ? how far
0 · Reply
BitcoinBankers
BitcoinBankers Aug. 4 at 8:21 AM
Ticker GYRO is exploding in pre-market!! Could GYRO be todays big squeeze?! news just released.. 700k shares float.. watchers on GYRO are growing very fast. Would not be surprised if GYRO is todays big 300% runner. 20$+ break could send her parabolic! $TMC $TLRY $SNDL $SONN momentum
0 · Reply
Stiochi
Stiochi Aug. 2 at 6:40 PM
$FIG $HYPD $SONN Just feel regret I didn't sell at 16.50 with almost 800% but at least I sold on Monday with 400% and all in with FIG.. Will back again GLTA
0 · Reply
CometaMan
CometaMan Aug. 2 at 3:50 PM
$SONN What are your projections for next week? Is it $1.35 or $13.50?
1 · Reply
ebk81
ebk81 Aug. 1 at 10:01 PM
$SONN wow.. now that's cold that's really fucked up no shame to do that to shareholders!! how to invest and be on the 99%?
0 · Reply
dbr_island
dbr_island Aug. 1 at 9:47 PM
$VYNE anyone here have at least 100,000 shares? $SONN $PBM $XCUR $OTRK are some of today’s AH movers
1 · Reply
LORAXX
LORAXX Aug. 1 at 9:35 PM
$SONN
0 · Reply